Notably, regenerative medicine was one of the most frequently referenced themes in Q2 2023, ranking highest in terms of mentions, ahead of edtech and metaverse, according to GlobalData.

Of the top leading companies in the medical industry, Bio-Techne had the greatest increase in references for regenerative medicine in Q2 2023, compared with the previous quarter. GlobalData identified 19 regenerative medicine-related sentences in the company's filings - 2% of all sentences - and an increase of 12% in Q2 2023 compared with Q2 2022. Cooper’s mentions of regenerative medicine rose by 88% to 15 and Thermo Fisher Scientific’s by 400% to 10 and Illumina’s by 100% to 2 and Agilent Technologies’s by 50% to 1.

GlobalData’s Company Filings Analytics also applies sentiment weight to reference sentences, based on whether the sentences are positive, negative, or neutral. Starting at 100 in 2020, an index over 100 is more positive. The overall index for regenerative medicine in Q2 2023 was 97.

For further understanding of GlobalData's Regenerative Medicine in Medical - Thematic Research buy the report here.

This content was updated on 5 August 2023

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Company Filings Analytics uses machine learning to uncover key insights and track sentiment across millions of regulatory filings and other corporate disclosures for thousands of companies across the world’s largest industries.